Balinatunfib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Balinatunfib
- Molecular weight
- 502.53
- Structure (SMILES)
- CN1C(=O)c2cccc(OC(F)F)c2[C@H]2C[C@@H]1c1nc3ccc(-c4cnc(C5(N)CCC5)nc4)cc3n12
- balinatunfib
- Balinatunfib
- balinatunfib [INN]
- BALINATUNFIB [USAN]
- Balinatunfib [WHO-DD]
- balinatunfib inn
- balinatunfib usan
- balinatunfib who dd
- sar 441566
- SAR-441566
- sar441566
- SAR441566
- CAS registry numbers
- 2248726-53-4
- ChEMBL ID
- CHEMBL6068043
- InChIKey
- UROFXMLQPAUCGV-WOJBJXKFSA-N
- PubChem compound IDs
- 132042903
- FDA ingredient codes (UNII)
- PLY98MAN4C
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- balinatunfib
- Type
- Synthetic organic
Mechanisms of action
- Action
- Binding
- Action type
- Binding
- Target
- tumour necrosis factor shed form
- Gene symbol
- tumour necrosis factor shed form
- Median affinity
- 7.82
- Affinity units
- pKd
- Condition identifier
- MONDO_0005011
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 2
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 1
- Polar surface area
- 99.16
- Calculated partition coefficient (ALogP)
- 4.55
- Calculated partition coefficient (XLogP)
- 2.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 4
- Heavy atoms
- 37
- Molecular formula
- C27H24F2N6O2
- Monoisotopic mass
- 502.19288035
- Natural product
- No
Related records
Trials (9)
- A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566
- A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.
- A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
- A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
- A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
- A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
- A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
- A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis
- A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS)